EP Patent

EP1593671A1 — DPP-IV inhibitors

Assigned to Graffinity Pharmaceuticals AG · Expires 2005-11-09 · 21y expired

What this patent protects

The invention relates to compounds of formula (I) Z-C(R<1>R<2>)-C(R<3>NH2)-C(R<4>R<5>)-X-N(R<6>R<7>) wherein Z, R<1-7> and X have the meaning as cited in the description and the claims. Said compounds are useful as DPP-IV inhibitors…

USPTO Abstract

The invention relates to compounds of formula (I) Z-C(R<1>R<2>)-C(R<3>NH2)-C(R<4>R<5>)-X-N(R<6>R<7>) wherein Z, R<1-7> and X have the meaning as cited in the description and the claims. Said compounds are useful as DPP-IV inhibitors. The invention also relates to the preparation of such compounds as well as the production and use thereof as medicament.

Drugs covered by this patent

Patent Metadata

Patent number
EP1593671A1
Jurisdiction
EP
Classification
Expires
2005-11-09
Drug substance claim
No
Drug product claim
No
Assignee
Graffinity Pharmaceuticals AG
Source
FDA Orange Book + USPTO grounding via Google Patents

Bibliographic data sourced from FDA Orange Book + USPTO public records. Plain-English summary generated by AI grounded in source text. Patent term extensions (PTR, SPC, pediatric) may shift the effective expiry. Not legal advice.

Track this patent

Get a daily-checked alert when vulnerability score, expiry, classification, or assignee changes. Email, Slack, or Teams delivery. Pro: 50 watches, Free: 3.